Your Location：
Home >
Browse articles >
AKR1C3 as a therapeutic target to overcome erlotinib resistance in lung adenocarcinoma
LETTER TO THE EDITOR | Updated：2025-12-13

    • AKR1C3 as a therapeutic target to overcome erlotinib resistance in lung adenocarcinoma

    • “In the field of xxx, expert xx has made significant research progress. By establishing the xx system/exploring the xx topic/verifying the xx conjecture, they have provided solutions to address xx problems/open up a new direction for xx research/lay a foundation for the construction of the xx system.”
    • Military Medical Research   Vol. 12, Issue 10, Pages: 1667-1669(2025)

    • DOI：10.1186/s40779-025-00593-4    

      CLC：

    • Received：29 October 2024，

      Accepted：13 January 2025，

      Online First：17 February 2025，

      Published：2025-10

    Scan QR Code

  • William C. Cho, Kwan P. Li, Chi F. Wong, et al. AKR1C3 as a therapeutic target to overcome erlotinib resistance in lung adenocarcinoma[J]. Military Medical Research, 2025, 12(10): 1667-1669. DOI： 10.1186/s40779-025-00593-4.

  •  
  •  

0

Views

0

Downloads

0

CSCD

Alert me when the article has been cited
Submit
Tools
Download
Export Citation
Share
Add to favorites
Add to my album

Related Articles

No data

Related Author

William C. Cho

Related Institution

No data
0